Open-label, add-on trial of cetirizine for neuromyelitis optica
Neurology® Neuroimmunology & Neuroinflammation Feb 14, 2018
Sand IK, et al. - During this trial, the efficacy and tolerability of cetirizine were gauged by the authors as an add-on to standard therapy for neuromyelitis optica (NMO). Findings revealed that the Epworth Sleepiness Scale (ESS) remained fairly consistent throughout the study. Hence, it was determined that the addition of cetirizine to standard therapy was safe and well tolerated in patients with NMO. It also led to a reduction in the relapses.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries